HAART to Heart: Highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 6, 2012, Pages 661-674

  Lipshultz, Steven E ^a,b   Mas, Catherine M ^a   Henkel, Jacqueline M ^a   Franco, Vivian I ^a   Fisher, Stacy D ^c   Miller, Tracie L ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; antiretroviral therapy; cardiovascular disease; heart; HIV; vasculature

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; ATAZANAVIR; CALCIUM CHANNEL BLOCKING AGENT; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PREDNISONE; QUINIDINE; QUININE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TESAMORELIN; UNINDEXED DRUG;

ADULT; ADULT DISEASE; BLOOD VESSEL INJURY; BODY FAT DISTRIBUTION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR DISEASE; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DYSLIPIDEMIA; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INFECTION PREVENTION; LIPODYSTROPHY; MOLECULAR PATHOLOGY; MORBIDITY; MORTALITY; MYOPATHY; NONHUMAN; PERICARDIAL EFFUSION; PR INTERVAL; PREDICTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STRESS ECHOCARDIOGRAPHY; VIRUS TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; RISK; RISK FACTORS;

EID: 84863204919     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.53     Document Type: Review

References (121)

1. Cohen SM, Van Handel MM, Branson BM et al. Vital signs: HIV prevention through care and treatment - United States. Morb. Mortal. Wkly Rep. 60(47), 1618-1623 (2011).
2. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 352(1), 48-62 (2005). (Pubitemid 40075680)
3. Caron-Debarle M, Boccara F, Lagathu C et al. Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations. Curr. Pharm. Des. 16(30), 3352-3360 (2010).
4. Galli M, Ridolfo AL, Adorni F et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J. Acquir. Immun. Defic. Syndr. 29(1), 21-31 (2002). (Pubitemid 34094303)
5. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 17(8), 1179-1193 (2003). (Pubitemid 36667761)
6. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356(17), 1723-1735 (2007). (Pubitemid 46658704)
7. Annamalia L, Westmoreland SV, Domingues HG, Walsh DG, Gonzalez RG, ONeil SP. Myocarditis in CD8-depleted SIV-infected rhesus macaques after short-term dual therapy with nucleoside and nucleoside reverse transcriptase inhibitors. PLos ONE 5(12), E14429 (2010).
8. Reinsch N, Neuhaus K, Esser S et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur. J. Prev. Cardiolog. 19(2), 267-274 (2012).
9. Sliwa K, Carrington MJ, Becker A, Thienemann F, Ntsekhe M, Stewart S. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur. Heart J. 33(7), 866-874 (2012).
10. Mondy KE, Gottdiener J, Overton ET et al. High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 52(3), 378-386 (2011).
11. Lipshultz SE. The cardiovascular manifestations of HIV infection. Dialogues Cardiovasc. Med. 12(1), 5 (2007).
12. Fisher SD, Lipshultz SE. Epidemiology of cardiovascular involvement in HIV disease and AIDS. Ann. NY Acad. Sci. 946, 13-22 (2001). (Pubitemid 33127206)
13. Butt AA, Chang CC, Kuller L et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch. Intern. Med. 171(8), 737-743 (2011).
14. Felker GM, Thompson RE, Hare JM et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med. 342(15), 1077-1084 (2000). (Pubitemid 30207690)
15. Herskowitz A, Wu TC, Willoughby SB et al. Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J. Am. Coll. Cardiol. 24(4), 1025-1032 (1994). (Pubitemid 24306414)
16. Lipshultz SE, Fisher SD, Lai WW, Miller TL. Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 17(Suppl. 1), S96-S122 (2003). (Pubitemid 36667787)
17. Wever Pinzon O, Silva Enciso J, Romero J et al. Risk stratification and prognosis of human immunodificiency virus-infected patients with known or suspected coronary artery disease referred for stress echocardiography. Circ. Cardiovasc. Imag. 4(4), 363-370 (2011).
18. Wever Pinzon O, Bangalore S, Romero J, Silva Enciso J, Chaudhry FA. Inotropic contractile reserve can risk-stratify patients with HIV cardiomyopathy a dobutamine stress echocardiography study. JACC Cardiovasc. Imag. 4(12), 1231-1238 (2011).
19. Carrillo-Jimenez R, Treadwell TL, Goldfine H, Buenano A, Lamas GA, Hennekens CH. Brain natriuretic peptide and HIV-related cardiomyopathy. AIDS Read. 12(11), 501-503, 508 (2002).
20. Duprez DA, Neuhaus J, Tracy R et al. N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. AIDS 25(5), 651-657 (2011).
21. Lipshultz SE, Fox CH, Perez-Atayde AR et al. Identification of human immunodeficiency virus-1 RNA and DNA in the heart of a child with cardiovascular abnormalities and congenital acquired immune deficiency syndrome. Am. J. Cardiol. 66(2), 246-250 (1990). (Pubitemid 20235744)
22. Orenstein JM. Replication of HIV-1 in vivo and in vitro. Ultrastruct. Pathol. 31(2), 151-167 (2007). (Pubitemid 47037182)
23. Reinsch N, Neuhaus K, Esser S et al. Prevalence of cardiac diastolic dysfunction in HIV-infected patients: results of the HIV-HEART study. HIV Clin. Trials 11(3), 156-162 (2010).
24. Nayak G, Ferguson M, Tribble DR et al. Cardiac diastolic dysfunction is prevalent in HIV-infected patients. AIDS Patient Care STDS 23(4), 231-238 (2009).
25. Luo L, Ye Y, Liu Z et al. Assessment of cardiac diastolic dysfunction in HIV-infected people without cardiovascular symptoms in China. Int. J. STD AIDS 21(12), 814-818 (2010).
26. Grandi AM, Nicolini E, Giola M et al. Left ventricular remodelling in asymptomatic HIV infection on chronic HAART: comparison between hypertensive and normotensive subjects with and without HIV infection. J. Hum. Hypertens. doi:10.1038/jhh.2011.81 (2011) (Epub ahead of print).
27. Seoane L, Shellito J, Welsh D, De Boisblanc BP. Pulmonary hypertension associated with HIV infection. South Med. J. 94(6), 635-639 (2001). (Pubitemid 33641190)
28. Limsukon A, Saeed AI, Ramasamy V, Nalamati J, Dhuper S. HIV-related pulmonary hypertension. Mt Sinai J. Med. 73(7), 1037-1044 (2006). (Pubitemid 46040407)
29. Nunes H, Humbert M, Sitbon O et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 167(10), 1433-1439 (2003). (Pubitemid 36609730)
30. Fisher SD, Lipshultz SE. Cardiovascular abnormalities in HIV-infected individuals. In: Braunwalds Heart Disease. A Textbook of Cardiovascular Medicine (Ninth Edition and Electronic Edition.) Bonow RO, Libby P, Mann DL, Zipes DP, Braunwald E (Eds). Elsevier Saunders, PA, USA, 1618-1627 (2011).
31. Heidenreich PA, Eisenberg MJ, Kee LL et al. Pericardial effusion in AIDS. Incidence and survival. Circulation 92(11), 3229-3234 (1995).
32. Lind A, Reinsch N, Neuhaus K et al. Pericardial effusion of HIV-infected patients? Results of a prospective multicenter cohort study in the era of antiretroviral therapy. Eur. J. Med. Res. 16(11), 480-483 (2011).
33. Nanavati KA, Fisher SD, Miller TL, Lipshultz SE. HIV-related cardiovascular disease and drug interactions. Am. J. Cardiovasc. Drugs 4(5), 315-324 (2004). (Pubitemid 39429837)
34. Askgaard G, Kristoffersen US, Mehlsen J, Kronborg G, Kjaer A, Lebech AM. Decreased heart rate variability in HIV positive patients receiving antiretroviral therapy: importance of blood glucose and cholesterol. PLoS ONE 6(5), E20196 (2011).
35. Lipshultz SE, Orav EJ, Sanders SP, Hale AR, Mcintosh K, Colan SD. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N. Engl. J. Med. 327(18), 1260-1265 (1992).
36. Mikhail IJ, Purdy JB, Dimock DS et al. High rate of coronary artery abnormalities in adolescents and young adults infected with human immunodeficiency virus early in life. Pediatr. Infect. Dis. J. 30(8), 710-712 (2011).
37. Lipshultz SE, Easley KA, Orav EJ et al. Cardiac dysfunction and mortality in HIV-infected children: the prospective P2C2 HIV multicenter study. Pediatric pulmonary and cardiac complications of vertically transmitted HIV infection (P2C2 HIV) Study Group. Circulation 102(13), 1542-1548 (2000).
38. Fisher SD, Easley KA, Orav EJ et al. Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P2C2 HIV multicenter study. Am. Heart J. 150(3), 439-447 (2005). (Pubitemid 41317610)
39. Luginbuhl LM, Orav EJ, Mcintosh K, Lipshultz SE. Cardiac morbidity and related mortality in children with HIV infection. JAMA 269(22), 2869-2875 (1993). (Pubitemid 23157011)
40. Al-Attar I, Orav EJ, Exil V, Vlach SA, Lipshultz SE. Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. J. Am. Coll. Cardiol. 41(9), 1598-1605 (2003). (Pubitemid 36543381)
41. Lipshultz SE, Orav EJ, Sanders SP, Colan SD. Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation 92(8), 2220-2225 (1995).
42. Dube MP, Lipshultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, Fisher SD. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 118(2), E36-E40 (2008).
43. Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF. Cardiovascular disease in HIV infection. Am. Heart J. 151(6), 1147-1155 (2006). (Pubitemid 44172869)
44. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J. Infect. Dis. 185(4), 456-462 (2002). (Pubitemid 34142807)
45. Torriani FJ, Komarow L, Parker RA et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) study 5152s. J. Am. Coll. Cardiol. 52(7), 569-576 (2008).
46. Ross AC, Storer N, ORiordan MA, Dogra V, McComsey GA. Longitudinal changes in carotid intima-media thickness and cardiovascular risk factors in human immunodeficiency virus-infected children and young adults compared with healthy controls. Pediatr. Infect. Dis. J. 29(7), 634-638 (2010).
47. Ross AC, ORiordan MA, Storer N, Dogra V, McComsey GA. Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis 211(2), 492-498 (2010).
48. Charakida M, Donald AE, Green H et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation 112(1), 103-109 (2005). (Pubitemid 40962575)
49. Miller TL, Somarriba G, Orav EJ et al. Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1. J. Acquir. Immun. Defic. Syndr. 55(2), 182-188 (2010).
50. Miller T, Borkowsky W, Dimeglio L et al. Pediatric HIV/AIDS Cohort Study (PHACS). Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med. 13(5), 264-275 (2011).
51. Conaldi PG, Serra C, Dolei A et al. Productive HIV-1 infection of human vascular endothelial cells requires cell proliferation and is stimulated by combined treatment with interleukin-1b plus tumor necrosis factor-a. J. Med. Virol. 47(4), 355-363 (1995). (Pubitemid 26022312)
52. Ren Z, Yao Q, Chen C. HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells. Lab. Invest. 82(3), 245-255 (2002). (Pubitemid 34242518)
53. Bukrinsky M, Sviridov D. Human immunodeficiency virus infection and macrophage cholesterol metabolism. J. Leukoc. Biol. 80(5), 1044-1051 (2006). (Pubitemid 44646310)
54. Gupta SK, Johnson RM, Saha C et al. Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study. AIDS 22(5), 653-655 (2008). (Pubitemid 351640600)
55. Fisher SD, Kanda BS, Miller TL, Lipshultz SE. Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIV-infected patients. Am. J. Cardiovasc. Drugs 11(6), 383-394 (2011).
56. Fitch K, Grinspoon S. Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients. Am. J. Clin. Nut. 94(6), 1721S-1728S (2011).
57. Lewis W, Kohler JJ, Hosseini SH et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol g hypothesis. AIDS 20(5), 675-684 (2006). (Pubitemid 43884294)
58. Gerschenson M, Erhart SW, Paik CY et al. Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3-azido-3- deoxythymidine. AIDS Res. Hum. Retroviruses 16(7), 635-644 (2000). (Pubitemid 30235989)
59. Gerschenson M, Poirier MC. Fetal patas monkeys sustain mitochondrial toxicity as a result of in utero zidovudine exposure. Ann. NY Acad Sci. 918, 269-281 (2000).
60. Torres SM, March TH, Carter MM et al. In utero exposure of female CD-1 mice to AZT and/or 3TC: I. persistence of microscopic lesions in cardiac tissue. Cardiovasc. Toxicol. 10(1), 37-50 (2010).
61. Torres SM, Divi RL, Walker DM et al. In utero exposure of female CD-1 mice to AZT and/or 3TC: II. persistence of functional alterations in cardiac tissue. Cardiovasc. Toxicol. 10(2), 87-99 (2010).
62. Chan SS, Santos JH, Meyer JN et al. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. Environ. Mol. Mutagen. 48(3-4), 190-200 (2007). (Pubitemid 46536087)
63. DAscenzo F, Cerrato E, Biondi-Zoccai G et al. Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy. Eur. Heart. J. 33(7), 875-880 (2012).
64. Yan Q. Acute effects of HIV protease inhibitors on the failing heart. Antiviral. Ther. 11(Suppl. 3), L11 (2006).
65. Hunt K, Hughes CA, Hills-Nieminen C. Protease inhibitor-associated QT interval prolongation. Ann. Pharmacother. 45(12), 1544-1550 (2011).
66. Charbit B, Gayat E, Voiriot P, Boccara F, Girard PM, Funck-Brentano C. Effects of HIV protease inhibitors on cardiac conduction velocity in unselected HIV-infected patients. Clin. Pharmacol. Ther. 90(3), 442-448 (2011).
67. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy and risk of acute myocardial infarction: a cohort and nested case-control study using Quebecs public health insurance database (RAMQ). J. Acquir. Immun. Defic. Syndr. 57(3), 245-253 (2011).
68. Ding X, Andraca-Carrera E, Cooper C et al. No association of myocardial infarction with ABC use: an FDA meta-analysis. Presented at: The 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA, USA, 27 February-2 March 2011.
69. Cruciani M, Zanichelli V, Serpelloni G et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 25(16), 1993-2004 (2011).
70. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 25(10), 1289-1298 (2011).
71. Lundgren JD, Neuhaus J, Babiker A et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22(4), F17-F24 (2008).
72. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12(7), F51-F58 (1998). (Pubitemid 28190689)
73. Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J. Acquir. Immun. Defic. Syndr. 49(Suppl. 2), S79-S85 (2008).
74. Barbaro G, Iacobellis G. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr. Diab. Rep. 9(1), 37-42 (2009).
75. Feeney ER, Mallon PW. HIV and HAART-associated dyslipidemia. Open. Cardiovasc. Med. J. 5, 49-63 (2011).
76. Worm SW, De Wit S, Weber R et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (D:A:D Study). Circulation 119(6), 805-811 (2009).
77. Butt AA. HIV infection and the risk of diabetes mellitus. AIDS 23(10), 1227-1234 (2009).
78. Miller TL, Orav EJ, Lipshultz SE et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J. Pediatr. 153(4), 491-497 (2008).
79. Jacobson DL, Patel K, Siberry GK et al. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the pediatric HIV/AIDS cohort study. Am. J. Clin. Nut. 94, 1485-1495 (2011).
80. Werner ML, Pone MV, Fonseca VM, Chaves CR. Lipodystrophy syndrome and cardiovascular risk factors in children and adolescents infected with HIV/AIDS receiving highly active antiretroviral therapy. J. Pediatr. (Rio J.) 86(1), 27-32 (2010).
81. Hurwitz BE, Klimas NG, Llabre MM et al. HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk: role of protease inhibitor exposure. Cardiovasc. Toxicol. 4(3), 303-316 (2004).
82. Clotet B, Bellos N, Molina JM et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369(9568), 1169-1178 (2007). (Pubitemid 46541620)
83. Johnson LB, Saravolatz LD. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin. Infect. Dis. 48(8), 1123-1128 (2009).
84. Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359(14), 1429-1441 (2008).
85. Macinnes A, Lazzarin A, Di Perri G et al. Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. HIV Clin. Trials 12(1), 24-36 (2011).
86. Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat. Rev. Drug Discov. 10(2), 95-96 (2011).
87. Fitch K, Abbara S, Lee H et al. Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS 26(5), 587-597 (2012).
88. Lipshultz SE. Increased left ventricular and aortic dimensions in long-term multiagent antiretroviral therapy (ART)-treated HIV-infected children: the NIH multicenter pediatric HIV/AIDS Cohort Study (PHACS). Circulation 120(Suppl. 18), S909 (2009).
89. Connor EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 331(18), 1173-1180 (1994). (Pubitemid 24331334)
90. Mofenson LM, Mcintyre JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 355(9222), 2237-2244 (2000). (Pubitemid 30394338)
91. Knapp KM, Brogly SB, Muenz DG et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr. Infect. Dis. J. 31(2), 164-170 (2012).
92. Lipshultz SE, Shearer WT, Thompson B et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART therapy in HIV-Exposed Infants and Children Cohort Study). J. Am. Coll. Cardiol. 57(1), 76-85 (2011).
93. Mas CM, Miller TL, Cordero C et al. The effects of fetal and childhood exposure to antiretroviral agents. J. AIDS Clinic. Res. doi:10.4172/21556-113. S20-01 (2011) (Epub ahead of print).
94. Lipshultz SE. Association of cardiac structure and function with in utero antiretroviral exposure among uninfected children born to HIV-infected mothers in the pediatric HIV/AIDS cohort study. Circulation 122(Suppl. 21), A16026 (2010).
95. Lipshultz SE, Easley KA, Orav EJ et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric pulmonary and cardiac complications of vertically transmitted HIV infection study group. N. Engl. J. Med. 343(11), 759-766 (2000).
96. Lipshultz SE. Antiretroviral therapy (ART) cardiac effects in HIV-infected children: the multicenter NHLBI Cardiac Highly Active Antiretroviral Therapy (CHAART-II) Study. Circulation 120(Suppl. 18), S909 (2009).
97. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 324(12), 808-815 (1991).
98. Lipshultz SE, Scully RE, Lipsitz SR et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 11(10), 950-961 (2010).
99. Lipshultz SE. Ventricular dysfunction clinical research in infants, children and adolescents. Prog. Pediatr. Cardiol. 12(1), 1-28 (2000).
100. Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104(3), 257-262 (2001). (Pubitemid 32666944)
101. Solages A, Vita JA, Thornton DJ et al. Endothelial function in HIV-infected persons. Clin. Infect. Dis. 42(9), 1325-1332 (2006).
102. Dube MP. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin. Infect. Dis. 47(4), 567-574 (2008).
103. Baker JV, Henry WK, Patel P et al. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin. Infect. Dis. 53(8), 826-835 (2011).
104. Fu W, Chai H, Yao Q, Chen C. Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression. J. Acquir. Immune Defic. Syndr. 39(2), 152-158 (2005). (Pubitemid 40741112)
105. Baliga RS, Liu C, Hoyt DG, Chaves AA, Bauer JA. Vascular endothelial toxicity induced by HIV protease inhibitor: evidence of oxidant-related dysfunction and apoptosis. Cardiovasc. Toxicol. 4(2), 199-206 (2004). (Pubitemid 39310752)
106. Dressman J, Kincer J, Matveev SV et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J. Clin. Invest. 111(3), 389-397 (2003). (Pubitemid 36182216)
107. Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J. Acquir. Immune Defic. Syndr. 44(5), 493-499 (2007). (Pubitemid 46594891)
108. Kappert K, Leppanen O, Paulsson J et al. Highly active antiretroviral therapy attenuates re-endothelialization and alters neointima formation in the rat carotid artery after balloon injury. J. Acquir. Immune Defic. Syndr. 43(4), 383-392 (2006). (Pubitemid 44737093)
109. Sutliff RL, Dikalov S, Weiss D et al. Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. Am. J. Physiol. Heart Circ. Physiol. 283(6), H2363-H2370 (2002). (Pubitemid 35345940)
110. Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in patients with HIV infection. Neurology 76(5), 444-450 (2011).
111. Rasmussen LD, Engsig FN, Christensen H et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS 25, 1637-1646 (2011).
112. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin. Infect. Dis. 53(1), 84-91 (2011).
113. Ferraioli G, Tinelli C, Maggi P et al. Arterial stiffness evaluation in HIV-positive patients: a multicenter matched control study. AJR Am. J. Roentgenol. 197(5), 1258-1262 (2011).
114. Maggi P, Serio G, Epifani G et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 14(16), F123-F128 (2000).
115. Hsue PY, Ordovas K, Lee T et al. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am. J. Cardiol. 109(5), 742-747 (2012).
116. Lorenz MW, Stephan C, Harmjanz A et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 196(2), 720-726 (2008).
117. Ghosh RK, Ghosh SM, Chawla S. Recent advances in antiretroviral drugs. Expert Opin. Pharmacother. 12(1), 31-46 (2011).
118. Triant VA, Josephson F, Rochester CG et al. Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease. Clin. Infect. Dis. 54(3), 408-413 (2011).
119. Joint United Nations Program on HIV/ AIDS (UNAIDS). UNAIDS World AIDS Day Report. www.unaids.org/en/media/unaids/ contentassets/documents/ unaidspublication/2011/JC2216-WorldAIDSday-report-2011-en.pdf
120. The White House, Office of the Press Secretary. Fact sheet: The beginning of the end of AIDS. www.whitehouse.gov/the-press-office/2011/12/01/fact-sheet- beginning-end-aids
121. The White House, Office of the Press Secretary. Remarks by the President on World AIDS Day. www.whitehouse.gov/the-press-office/2011/12/01/remarks- president-world-aids-day